8-K: Biote Corp. Announces $60 Million Share Repurchase Agreement to Resolve Litigation

Biote Corp. has agreed to repurchase approximately 8.3 million shares and cancel 4.0 million earnout shares from a stockholder for $60 million to resolve litigation.

Summary

• Biote Corp. has entered into a binding settlement term sheet to resolve litigation with stockholder Marci M. Donovitz.
• The agreement involves Biote repurchasing approximately 8.3 million shares of its stock from Donovitz for a total of $60 million.
• The repurchase will occur over a three-year period, with $30 million paid on or before June 28, 2024, and the remaining $30 million paid in three $10 million installments on the 12, 24, and 36-month anniversaries of the closing date.
• Additionally, Biote will cancel approximately 4.0 million earnout shares owned by Donovitz for no additional monetary consideration.
• The average price per share for the repurchased shares is $7.23.
• The settlement also includes a mutual release of claims, a voting agreement, and acceleration of the purchase schedule in the event of a change of control.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment due to the resolution of litigation, share repurchase, and cancellation of earnout shares, which are all expected to benefit shareholders. However, the company is spending a significant amount of capital and there are risks associated with the business.

Positives

• The share repurchase is expected to contribute to long-term shareholder value.
• The cancellation of earnout shares simplifies the company's capital structure.
• The settlement resolves outstanding litigation with a key stockholder.
• The company views the aggregate price of the transaction as attractive.
• The repurchase is consistent with the company's capital allocation strategy.

Negatives

• The company will spend $60 million on the share repurchase.
• The repurchase will occur over a three-year period, which may delay the full impact of the transaction.
• The company is using its existing capital allocation strategy to fund the repurchase.

Risks

• The company's success depends on the market acceptance of its dietary supplements.
• The company relies on third parties for the manufacturing of bio-identical hormones.
• The company is sensitive to regulatory, economic, environmental, and competitive conditions.
• The company faces significant competition in its industry.
• The company's ability to grow its business is subject to various factors.
• The company is subject to heavy regulatory oversight.
• Changes in laws or regulations could adversely impact the company.
• The company may be impacted by economic, business, and competitive factors, including bank failures.
• Future exchange and interest rates could impact the company.

Future Outlook

The company intends to continue focusing on driving profitable growth and establishing itself as a leader in evidence-based therapeutic wellness. The company also intends to fund the repurchases in accordance with its existing capital allocation strategy.

Management Comments

• Terry Weber, Biote Chief Executive Officer, stated that they are pleased to reach an agreement that enables them to repurchase approximately 8.3 million shares and cancel approximately 4.0 million earnout shares.
• Bob Peterson, Biote Chief Financial Officer, said that the agreement represents an advantageous use of capital that they believe will contribute to long-term shareholder value.

Industry Context

This announcement is related to the company's efforts to manage its capital structure and resolve outstanding litigation, which is a common practice in the healthcare and pharmaceutical industry. The share repurchase and cancellation of earnout shares are aimed at improving shareholder value and simplifying the company's financial structure.

Comparison to Industry Standards

• Share repurchases are a common method for companies to return value to shareholders, especially when they believe their stock is undervalued.
• The average price of $7.23 per share is a key metric to compare against the current market price of Biote's stock to assess the value of the repurchase.
• The cancellation of earnout shares is a positive move to reduce potential future dilution and simplify the capital structure, similar to actions taken by other companies in the sector.
• Companies like AbbVie and Amgen have also engaged in share repurchases to enhance shareholder value, although the scale and specific circumstances may differ.

Legal Proceedings

• The company has entered into a settlement term sheet to resolve litigation with Marci M. Donovitz.

Stakeholder Impact

• Shareholders are expected to benefit from the share repurchase and cancellation of earnout shares.
• The resolution of litigation is expected to reduce uncertainty for stakeholders.
• The company's focus on profitable growth is expected to benefit all stakeholders.

Next Steps

• The company will prepare and enter into a definitive settlement agreement.
• The company will repurchase approximately 4.1 million shares by June 28, 2024.
• The company will repurchase the remaining shares over the next three years.
• The company will file the settlement term sheet in its next quarterly report on Form 10-Q.

Key Dates

Keywords

share repurchase, litigation settlement, earnout shares, capital allocation, stockholder agreement, biote, BTMD, hormone optimization, therapeutic wellness